About Us
Cloudbreak Pharma is a clinical stage ophthalmic drug company, founded September 2015 in Irvine, CA, USA. Our team has diverse skill sets and extensive ocular drug R&D experience.
Cloudbreak Pharma operates a capital efficient business model mostly based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and carry out Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.
In addition to repurposing approved oral drugs for ocular use, we also have several early stage innovative programs, ranging from low risk formulation improvement of known ocular drugs, to higher risk development of new chemical entity (NCE) and biologics drugs for ocular indications with unmet needs.
The Cloudbreak Pharma management team has extensive experience with ocular drug discovery and development. In addition, Cloudbreak Pharma is supported by seasoned advisers and consultants.
Management
Jinsong Ni, Ph.D
Founder, Chief Executive Officer
Rebecca Chan, CPA, MBA, LLB
Director, Chief Financial Officer
Abu Abraham, MD
Chief Medical Officer
Van Dinh, MBA
Chief Operating Officer
Rong Yang, Ph.D
Chief Scientific Officer
Greg Brooks, B.Sc
Chief Commercial Officer
